ZURICH – Novartis AG said on Tuesday a U.S. court of appeals upheld the validity of a dosage regimen patent for its multiple sclerosis treatment Gilenya, allowing a permanent injunction …
Shore News Network is a free website that does not use paywalls or charge for access to original, breaking news content. In order to provide this free service, we rely on advertisements. Please support our journalism by disabling your ad blocker for this website.